{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:50:56Z","timestamp":1787028656073,"version":"build-2736575974"},"reference-count":31,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T00:00:00Z","timestamp":1740700800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background: Untreated bipolar disorder during pregnancy is associated with poor prenatal care, decreased fetal growth, and an increased risk for postnatal complications, including postpartum psychosis. Although mood stabilizers are first-line therapy, many patients and providers discontinue them in early pregnancy. Antidepressants as monotherapy can increase the risk of mania and rapid cycling, especially in patients with bipolar I, and are not recommended. Objective: This study aims to describe prescribing patterns for the pharmacologic management of bipolar disorder in pregnancy. Methods: This retrospective cohort study included pregnant patients, \u226514 years old, with a documented diagnosis of bipolar disorder and \u2265two clinic visits after 1 January 2014, who delivered by 31 October 2017, within our health system. Eligible patients were identified by the ICD-9 and ICD-10 codes for bipolar disorder and their medication profiles. The primary outcome was to describe bipolar disorder treatment regimens at first visit, during pregnancy, and at delivery. Descriptive statistics were used. Results: Of the 214 pregnancies analyzed, 134 (62.6%) used psychiatric medications during pregnancy, with 79\/134 (59%) being mood stabilizers. During the initial visit, 61\/214 (28.5%) pregnancies were on psychiatric medications, including 30 (49.2%) on mood stabilizers and 16 (26.2%) on antidepressants alone. At delivery, 98\/214 (45.8%) pregnancies were on psychiatric medications, with 48\/98 (49%) on mood stabilizers and 35\/98 (35.7%) on antidepressants without mood stabilizers. Other therapies included benzodiazepines, buspirone, and amphetamines, as monotherapy or combination. Conclusions: Despite having documented bipolar disorder, only 30\/214 (14%), 79\/214 (36.9%), and 48\/214 (22.4%) pregnancies were treated with mood stabilizers at the first visit, during pregnancy, and at delivery, respectively. Unfortunately, justification for discontinuation was not documented. The most commonly prescribed mood stabilizer was lurasidone, followed by lamotrigine. Antidepressant monotherapy persisted throughout pregnancy, demonstrating inappropriate disease management.<\/jats:p>","DOI":"10.3390\/jcm14051638","type":"journal-article","created":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T02:48:37Z","timestamp":1740710917000},"page":"1638","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Prescribing Patterns for the Treatment of Bipolar Disorder in Pregnancy: A Retrospective Cohort Study"],"prefix":"10.3390","volume":"14","author":[{"given":"Nalino\u00eb J.","family":"Kernizan","sequence":"first","affiliation":[{"name":"Department of Pharmacy Practice, St. Louis College of Pharmacy, University of Health Sciences and Pharmacy, St. Louis, MO 63110, USA"},{"name":"SSM Health St. Mary\u2019s Hospital, St. Louis, MO 63132, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abigail M.","family":"Yancey","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, St. Louis College of Pharmacy, University of Health Sciences and Pharmacy, St. Louis, MO 63110, USA"},{"name":"SSM Health St. Mary\u2019s Hospital, St. Louis, MO 63132, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia B.","family":"Forinash","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, St. Louis College of Pharmacy, University of Health Sciences and Pharmacy, St. Louis, MO 63110, USA"},{"name":"SSM Health St. Mary\u2019s Hospital, St. Louis, MO 63132, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niraj R.","family":"Chavan","sequence":"additional","affiliation":[{"name":"SSM Health St. Mary\u2019s Hospital, St. Louis, MO 63132, USA"},{"name":"Division of Maternal-Fetal Medicine, Saint Louis University School of Medicine, St. Louis, MO 63117, USA"},{"name":"Department of Obstetrics, Gynecology, and Women\u2019s Health, Saint Louis University School of Medicine, St. Louis, MO 63117, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine J.","family":"Mathews","sequence":"additional","affiliation":[{"name":"SSM Health St. Mary\u2019s Hospital, St. Louis, MO 63132, USA"},{"name":"Division of Maternal-Fetal Medicine, Saint Louis University School of Medicine, St. Louis, MO 63117, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,2,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Rusner, M., Berg, M., and Begley, C. (2016). Bipolar disorder in pregnancy and childbirth: A systematic review of outcomes. BMC Pregnancy Childbirth, 16.","DOI":"10.1186\/s12884-016-1127-1"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"American College of Obstetrics and Gynecology (2023). Screening and diagnosis of mental health conditions during pregnancy and postpartum. Clinical Practice Guideline No. 4. Obstet. Gynecol., 141, 1232\u20131261.","DOI":"10.1097\/AOG.0000000000005200"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"21r14045","DOI":"10.4088\/JCP.21r14045","article-title":"Prevalence of bipolar disorder in perinatal women: A systematic review and meta-analysis","volume":"83","author":"Masters","year":"2022","journal-title":"J. Clin. Psychiatry"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"American College of Obstetricians and Gynecologists (2023). ACOG Practice Bulletin No. 92. Treatment and management of mental health conditions during pregnancy and postpartum. Obstet. Gynecol., 141, 1262\u20131288.","DOI":"10.1097\/AOG.0000000000005202"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Bramante, A., and Di Florio, A. (2023). A case-control study of filicide\/infanticide in 90 mothers. Arch. Women\u2019s Ment. Health, 1\u20137.","DOI":"10.1007\/s00737-023-01401-5"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.genhosppsych.2022.05.009","article-title":"Perspectives on addressing bipolar disorder in the obstetric setting","volume":"77","author":"Masters","year":"2022","journal-title":"Gen. Hosp. Psychiatry"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1176\/appi.ajp.2015.15010124","article-title":"Risk of postpartum relapse in bipolar disorder and postpartum psychosis: A systematic review and meta-analysis","volume":"173","author":"Wesseloo","year":"2016","journal-title":"Am. J. Psychiatry"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Margiotta, C., Gao, J., O\u2019Neil, S., Vohra, D., and Zivin, K. (2022). The economic impact of untreated maternal mental health conditions in Texas. BMC Pregnancy Childbirth, 22.","DOI":"10.1186\/s12884-022-05001-6"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/bdi.12609","article-title":"Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder","volume":"20","author":"Yatham","year":"2018","journal-title":"Bipolar Disord."},{"key":"ref_10","unstructured":"Lithium (2024, November 17). Lexi-Drugs, Available online: https:\/\/online.lexi.com."},{"key":"ref_11","unstructured":"DiPiro, J.T., Talbert, R.L., Yee, G.C., Matzke, G.R., Wells, B.G., and Posey, L.M. (2022). Pharmacotherapy: A Pathophysiologic Approach, Mc-Graw-Hill. [12th ed.]."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s40263-017-0433-0","article-title":"Pregnancy outcomes following in utero exposure to lamotrigine: A systematic review and meta-analysis","volume":"31","author":"Pariente","year":"2017","journal-title":"CNS Drugs"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1111\/bcpt.12372","article-title":"Pregnancy exposure to olanzapine, quetiapine, risperidone, aripiprazole and risk of congenital malformations. A systematic review","volume":"116","author":"Ennis","year":"2015","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1001\/jamapsychiatry.2022.4109","article-title":"Association of in utero antipsychotic medication exposure with risk of congenital malformations in Nordic countries and the US","volume":"80","author":"Huybrechts","year":"2023","journal-title":"JAMA Psychiatry"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"20m13745","DOI":"10.4088\/JCP.20m13745","article-title":"Reproductive safety of second-generation antipsychotics: Updated data from the Massachusetts General Hospital national pregnancy registry for atypical psychotics","volume":"82","author":"Viguera","year":"2021","journal-title":"J. Clin. Psychiatry"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"22m14492","DOI":"10.4088\/JCP.22m14492","article-title":"Risk of poor neonatal adaption syndrome among infants exposed to second-generation atypical antipsychotics compared to antidepressants: Results from the National Pregnancy Registry for Psychiatric Medications","volume":"84","author":"Viguera","year":"2023","journal-title":"J. Clin. Psychiatry"},{"key":"ref_17","unstructured":"National Institute of Mental Health (2024, November 17). Bipolar Disorder, Available online: https:\/\/www.nimh.nih.gov\/health\/topics\/bipolar-disorder#part_2264."},{"key":"ref_18","unstructured":"(2017). Latuda (Lurasidone), Sunovion Pharmaceuticals Inc. Prescribing Information."},{"key":"ref_19","unstructured":"U.S. Food and Drug Administration (2024, November 17). FDA Drug Safety Communication: Antipsychotic Drug Labels Updated on Use During Pregnancy and Risk of Abnormal Muscle Movements and Withdrawal Symptoms in Newborns, Available online: https:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm243903.htm#list."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1377\/hlthaff.2023.01439","article-title":"Increasing access to perinatal mental health care: The Perinatal Psychiatry Access Program Model","volume":"43","author":"Schaefer","year":"2024","journal-title":"Health Aff."},{"key":"ref_21","unstructured":"Missouri Perinatal Quality Care Collaborative (2025, February 22). 2024 Perinatal Mental Health Conditions Workbook. Missouri Perinatal Quality Care Collaborative. Available online: https:\/\/mopqc.org\/wp-content\/uploads\/2024\/08\/2024_Perinatal_Mental_Health_Conditions_Workbook_072224.pdf."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.euroneuro.2018.11.1103","article-title":"Psychopharmacological prescribing practices in pregnancy for women with severe mental illness: A multicentre study","volume":"29","author":"Galbally","year":"2019","journal-title":"Eur. Neuropsychopharmacol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1089\/jwh.2022.0310","article-title":"Reproductive safety of lurasidone and quetiapine update from the National Pregnancy Registry for psychiatric medications","volume":"32","author":"Cohen","year":"2023","journal-title":"J. Women\u2019s Health"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1037\/pha0000509","article-title":"Perinatal use of lurasidone for the treatment of bipolar disorder","volume":"30","author":"Montiel","year":"2022","journal-title":"Exp. Clin. Psychopharm."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1111\/bdi.13481","article-title":"Mood stabilizers for the treatment of bipolar disorder in pregnancy and impact on neonatal outcomes","volume":"26","author":"Kernizan","year":"2024","journal-title":"Bipolar Disord."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1001\/jamapsychiatry.2016.1520","article-title":"Antipsychotic use in pregnancy and the risk for congenital malformations","volume":"73","author":"Huybrechts","year":"2016","journal-title":"JAMA Psychiatry"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1176\/appi.ajp.2007.06101639","article-title":"Risk of recurrence in women with bipolar disorder during pregnancy: Prospective study of mood stabilizer discontinuation","volume":"164","author":"Viguera","year":"2007","journal-title":"Am. J. Psychiatry"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1176\/appi.ps.201600408","article-title":"Antipsychotic medication use among publicly insured pregnant women in the United States","volume":"68","author":"Park","year":"2017","journal-title":"Psychiatr. Serv."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.jad.2016.12.001","article-title":"Psychopharmacological drug utilization patterns in pregnant women with bipolar disorder\u2014A nationwide register-based study","volume":"210","author":"Broeks","year":"2017","journal-title":"J. Affect. Disord."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Hanley, G.E., and Mintzes, B. (2014). Patterns of psychotropic medicine use in pregnancy in the United States from 2006 to 2011 among women with private insurance. BMC Pregnancy Childbirth, 14.","DOI":"10.1186\/1471-2393-14-242"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1176\/appi.ajp.2014.13111501","article-title":"The risk of switch to mania in patients with bipolar disorder during treatment with an antidepressant alone and in combination with a mood stabilizer","volume":"171","author":"Viktorin","year":"2014","journal-title":"Am. J. Psychiatry"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/5\/1638\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:44:08Z","timestamp":1760028248000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/5\/1638"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,28]]},"references-count":31,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,3]]}},"alternative-id":["jcm14051638"],"URL":"https:\/\/doi.org\/10.3390\/jcm14051638","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,28]]}}}